Guggenheim analyst Michael Schmidt lowered the firm’s price target on Arvinas (ARVN) to $32 from $57 and keeps a Buy rating on the shares after updating the firm’s model and estimates following the announcement of topline results from the company’s Phase 3 VERITAC-2 clinical trial of ER-degrader vepdegestrant. Following the data, the firm is increasing its monotherapy success probability, lowering its odds of success assumption in second-line metastatic breast cancer as part of combinations in all-comers to 30% from 50% and removing its first-line mBC estimates, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Buy Rating for Arvinas Holding Company Amid Promising VERITAC-2 Trial Results and Potential Market Edge
- Arvinas downgraded to Neutral from Buy at Goldman Sachs
- PepsiCo downgraded, HubSpot upgraded: Wall Street’s top analyst calls
- Wedbush cuts Arvinas to Neutral as VERITAC-2 shows monotherapy strategy limited
- Arvinas price target lowered to $20 from $82 at BMO Capital